Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us

Lymphoma

Lymphoma Medicines in India: Imported Options for Hodgkin and Non-Hodgkin Types

Written by Nitin Goswami Medically reviewed by Dr. Chirag C Shah Last updated
QUICK ANSWERLymphoma is a cancer of the lymphocytes, the white cells that live in lymph nodes, spleen and other lymphoid tissue. Doctors divide it into Hodgkin lymphoma and non-Hodgkin lymphoma (NHL), and NHL is further split into B-cell types such as DLBCL, follicular and mantle cell lymphoma, and T-cell types such as PTCL and skin (cutaneous) T-cell lymphoma. GLOBOCAN puts India's 2024 total at 41,973 new NHL cases plus 9,973 new Hodgkin cases [1]. The biopsy report, with its exact subtype, decides which medicine can be considered. Through Named Patient Program (NPP), each of the 18 medicines on this page can be imported for a single named patient, against the written prescription of the treating hematologist or oncologist.
51,946
new lymphoma cases in India in 2024: 41,973 non-Hodgkin plus 9,973 Hodgkin
Source: IARC GLOBOCAN 2024 [1]
7.5%
of all new non-Hodgkin lymphoma worldwide was in India: 41,973 of 562,793 cases
Source: GLOBOCAN 2024 [1, 2]
46.9%
of 4,026 non-Hodgkin lymphomas diagnosed at CMC Vellore over ten years were DLBCL, the single largest subtype
Source: Leuk Lymphoma, 2013 [4]
17.4%
of 1,032 non-Hodgkin lymphomas seen at a South Indian referral centre were peripheral T-cell lymphomas (180 cases)
Source: Indian J Pathol Microbiol, 2012 [6]

Hodgkin, B-cell and T-cell lymphoma: how the groups differ

A pathologist names the lymphoma by looking at the biopsy under the microscope and by staining it for surface markers such as CD20, CD19 or CD30. That label matters more than the word "lymphoma" itself, because almost every imported medicine below is approved for one or two named subtypes only.

GroupCommon subtypesWhat Indian series foundMedicines on this page
Fast-growing B-cell NHLDiffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphomaDLBCL was the top NHL subtype at CMC Vellore [4] and in Bihar, where it made up 58% of NHL [5]Columvi, Epkinly, Zynlonta, Monjuvi, Minjuvi, Zuberitamab
Slow-growing B-cell NHLFollicular lymphoma (FL), small lymphocytic lymphoma (SLL)The Bihar team found follicular lymphoma less common in India than in Western reports [5]Epkinly (FL); Jaypirca, Lisaftoclax, Sonrotoclax (SLL)
Mantle cell lymphomaMCLAlso reported as less frequent in India than in the West [5]Jaypirca, Sonrotoclax
Hodgkin lymphomaClassical Hodgkin lymphoma (cHL)21.3% of 5,115 lymphomas at CMC Vellore; mixed cellularity was the leading subtype [4]Opdivo
T-cell lymphomaPeripheral T-cell lymphoma (PTCL), mycosis fungoides and Sézary syndrome (CTCL), T-lymphoblastic lymphomaT/NK-cell types formed 20.2% of NHL at Vellore, more than Western series show [4]Folotyn, Beleodaq, Zeprumetostat, Istodax, Poteligeo, Targretin, Zolinza, Atriance

How many people in India get lymphoma

For 2024, IARC's GLOBOCAN estimates list 41,973 new non-Hodgkin lymphoma cases in India, ranked 11th among all cancers, and 23,769 deaths from it. Hodgkin lymphoma added 9,973 new cases and 2,685 deaths [1]. Taken together that is 41,973 + 9,973 = 51,946 new cases and 23,769 + 2,685 = 26,454 deaths in a single year.

Across the world, the same programme counts 562,793 new NHL cases [2] and 84,495 new Hodgkin cases [3]. India's portion is therefore 41,973 ÷ 562,793 = 7.5% of NHL and 9,973 ÷ 84,495 = 11.8% of Hodgkin lymphoma.

The subtype mix in India is not the same as in Europe or the USA. In the CMC Vellore series of 5,115 lymphomas, peripheral T-cell and NK-cell lymphomas were more frequent than in Western data, and about one NHL in three (32.8%) started outside the lymph nodes, most often in the gut [4]. A Patna study of 518 cases noted that T-lymphoblastic and anaplastic large-cell lymphomas are seen more often in India [5].

What Indian treatment studies report

  • DLBCL responds well to rituximab-based treatment. Among 580 DLBCL patients at NRS Medical College, Kolkata (median age 55), 75% received R-CHOP and two-year overall survival was 81.4%. Complete response was 73% in the germinal centre type but 43% in the activated B-cell type [7].
  • Older patients do better on the full regimen when fit. At Tata Memorial Centre, 218 people aged 60 or over with DLBCL were reviewed: two-year progression-free survival was 79.1% with R-CHOP against 49.6% with the etoposide-based R-CEOP substitute [8].
  • Biosimilar rituximab gave similar results. A 29-centre Indian study of 1,365 DLBCL patients on two rituximab biosimilars reported two-year progression-free survival of 69% and overall survival of 78.7% [9].
  • Risk score shapes the outlook. In 214 adults with NHL treated at a Tata Memorial unit in Guwahati, five-year overall survival was 47.84% overall, 62.09% with a low-risk IPI score and 25.17% with a high-risk score [10].
  • Hodgkin lymphoma is highly curable. At Kidwai Memorial Institute, Bengaluru, 200 adults and teenagers with classical Hodgkin lymphoma (median age 28) had an 84.5% complete response rate and 84.1% overall survival at six years, even though 62.5% came with advanced stage [11]. In children with early-stage disease, the InPOG-HL-15-01 study across 27 Indian centres reported five-year overall survival of 95.5% [12].
  • Childhood B-cell NHL needs strong supportive care. In the InPOG-NHL-16-01 study of 191 children, Burkitt lymphoma made up 69.6% of cases, and treatment-related deaths (14.3%) were a major reason for lost cures [13].

Matching a relapse to a medicine

Most medicines listed here are meant for lymphoma that has come back or did not respond to earlier treatment. The table shows how the label wording lines up with each situation; the hematologist makes the final call.

SituationMedicines on this page
DLBCL that has failed two or more earlier linesColumvi, Epkinly, Zynlonta
DLBCL relapsed, transplant not possibleMonjuvi or Minjuvi, each given with lenalidomide
Newly diagnosed CD20-positive DLBCLZuberitamab with CHOP (China approval)
Follicular lymphoma that has relapsedEpkinly (with lenalidomide and rituximab, or alone after two lines)
Mantle cell lymphoma after a BTK inhibitorJaypirca, Sonrotoclax
Classical Hodgkin lymphoma, stage III–IV at diagnosis or after transplantOpdivo
PTCL that has relapsedFolotyn, Beleodaq, Zeprumetostat
Skin T-cell lymphoma after systemic treatmentIstodax, Poteligeo, Targretin, Zolinza

India also has its own CAR-T cell therapy. Talicabtagene autoleucel, the first humanised CD19 CAR-T approved in the country, was given to 145 people with relapsed or refractory B-cell NHL in a 56-centre Indian study; at 12 months, 63% were alive and 47% had no progression [14]. Ask your centre whether it is an option before choosing an imported medicine.

Imported lymphoma medicines by type

All 18 medicines below are prescription-only. Tap a type to filter. Each card opens the full medicine page with dosage, storage and safety details.

Columvi (glofitamab)
Columvi
glofitamab · IV infusion
CD20 x CD3 bispecific antibody for adult DLBCL (NOS), or large B-cell disease transformed from follicular lymphoma, once it has come back or resisted at least two prior treatment lines (accelerated approval)
Large B-cell (DLBCL) US FDA
Epkinly (epcoritamab)
Epkinly
epcoritamab · Subcutaneous injection
Adults whose DLBCL or high-grade B-cell lymphoma persists or returns despite two or more earlier lines; follicular lymphoma that has come back, given with lenalidomide plus rituximab, or alone once two lines have failed
Large B-cell (DLBCL)Follicular (FL) US FDA
Zynlonta (loncastuximab tesirine)
Zynlonta
loncastuximab tesirine · IV infusion
CD19-targeted antibody-drug conjugate for adults whose large B-cell lymphoma (DLBCL included) has returned or resisted two or more earlier lines (accelerated approval)
Large B-cell (DLBCL) US FDA
Monjuvi (tafasitamab)
Monjuvi
tafasitamab · IV infusion
With lenalidomide for adults with relapsed or refractory DLBCL, including DLBCL from low-grade lymphoma, for whom a transplant using their own stem cells is not suitable
Large B-cell (DLBCL) US FDA
Minjuvi (tafasitamab)
Minjuvi
tafasitamab · IV infusion
European brand of tafasitamab: with lenalidomide for adults with relapsed or refractory DLBCL who are unfit for a transplant of their own stem cells
Large B-cell (DLBCL) EMA (Europe)
Zuberitamab (zuberitamab)
Zuberitamab
zuberitamab · IV infusion
Anti-CD20 antibody added to CHOP chemotherapy as first treatment for adult CD20-positive DLBCL, NOS (approved in China, May 2023)
Large B-cell (DLBCL) China NMPA
Jaypirca (pirtobrutinib)
Jaypirca
pirtobrutinib · Tablet
Non-covalent BTK inhibitor: adult mantle cell lymphoma that relapsed after two or more lines, one of them a BTK inhibitor; also CLL/SLL, either as first treatment (no 17p deletion) or after a covalent BTK inhibitor
Mantle cell (MCL)Small lymphocytic (SLL) US FDA
Sonrotoclax (sonrotoclax)
Sonrotoclax
sonrotoclax · Tablet
BCL-2 blocker: in the US (as Beqalzi) for adult mantle cell lymphoma that returned after two or more lines, a BTK inhibitor among them; in China also for CLL/SLL previously given a BTK inhibitor
Mantle cell (MCL)Small lymphocytic (SLL) US FDA (as Beqalzi), China NMPA
Lisaftoclax (lisaftoclax)
Lisaftoclax
lisaftoclax · Tablet
BCL-2 blocker for adult CLL or SLL already treated, where earlier therapy included a BTK inhibitor (conditional approval in China, July 2025)
Small lymphocytic (SLL) China NMPA
Opdivo (nivolumab)
Opdivo
nivolumab · IV infusion
Classical Hodgkin lymphoma: first treatment of stage III/IV disease, with AVD chemotherapy, from age 12; or in adults whose disease came back after an own-cell transplant plus brentuximab vedotin, or after three or more lines that included such a transplant
Hodgkin (cHL) US FDA
Folotyn (pralatrexate)
Folotyn
pralatrexate · IV injection
Folate-pathway blocker for PTCL that has returned or stopped responding (accelerated approval)
Peripheral T-cell (PTCL) US FDA
Beleodaq (belinostat)
Beleodaq
belinostat · IV infusion
HDAC inhibitor for adult PTCL that has come back or not responded to earlier treatment (accelerated approval)
Peripheral T-cell (PTCL) US FDA
Zeprumetostat (zeprumetostat)
Zeprumetostat
zeprumetostat · Tablet
EZH2 blocker for adult PTCL that returned or resisted at least one earlier whole-body treatment (conditional approval in China, August 2025)
Peripheral T-cell (PTCL) China NMPA
Istodax (romidepsin)
Istodax
romidepsin · IV infusion
HDAC inhibitor for adult CTCL once one or more whole-body (systemic) treatments have been given
Skin T-cell (CTCL) US FDA
Poteligeo (mogamulizumab)
Poteligeo
mogamulizumab · IV infusion
CCR4 antibody for adult mycosis fungoides or Sézary syndrome that persists or returns after one or more systemic treatments
Skin T-cell (CTCL) US FDA
Targretin (bexarotene)
Targretin
bexarotene · Capsule
Retinoid capsule for the skin lesions of CTCL when one or more systemic treatments have failed
Skin T-cell (CTCL) US FDA
Zolinza (vorinostat)
Zolinza
vorinostat · Capsule
HDAC inhibitor capsule for CTCL skin lesions that keep growing, persist or return during or after two systemic treatments
Skin T-cell (CTCL) US FDA
Atriance (nelarabine)
Atriance
nelarabine · IV infusion
T-lymphoblastic lymphoma (and T-ALL) from age 1, when the disease returns or keeps going after two or more chemotherapy regimens
T-lymphoblastic (T-LBL) US FDA (as Arranon)

Compare all 18 lymphoma medicines

MedicineGeneric nameLymphoma typeFormApproved by
ColumviglofitamabLarge B-cell (DLBCL)IV infusionUS FDA
EpkinlyepcoritamabLarge B-cell (DLBCL), Follicular (FL)Subcutaneous injectionUS FDA
Zynlontaloncastuximab tesirineLarge B-cell (DLBCL)IV infusionUS FDA
MonjuvitafasitamabLarge B-cell (DLBCL)IV infusionUS FDA
MinjuvitafasitamabLarge B-cell (DLBCL)IV infusionEMA (Europe)
ZuberitamabzuberitamabLarge B-cell (DLBCL)IV infusionChina NMPA
JaypircapirtobrutinibMantle cell (MCL), Small lymphocytic (SLL)TabletUS FDA
SonrotoclaxsonrotoclaxMantle cell (MCL), Small lymphocytic (SLL)TabletUS FDA (as Beqalzi), China NMPA
LisaftoclaxlisaftoclaxSmall lymphocytic (SLL)TabletChina NMPA
OpdivonivolumabHodgkin (cHL)IV infusionUS FDA
FolotynpralatrexatePeripheral T-cell (PTCL)IV injectionUS FDA
BeleodaqbelinostatPeripheral T-cell (PTCL)IV infusionUS FDA
ZeprumetostatzeprumetostatPeripheral T-cell (PTCL)TabletChina NMPA
IstodaxromidepsinSkin T-cell (CTCL)IV infusionUS FDA
PoteligeomogamulizumabSkin T-cell (CTCL)IV infusionUS FDA
TargretinbexaroteneSkin T-cell (CTCL)CapsuleUS FDA
ZolinzavorinostatSkin T-cell (CTCL)CapsuleUS FDA
AtriancenelarabineT-lymphoblastic (T-LBL)IV infusionUS FDA (as Arranon)

Papers your doctor will ask for

DocumentWhy it matters
Biopsy with immunohistochemistryNames the subtype and shows markers such as CD20, CD19 or CD30
PET-CT or CT scan reportGives the stage, and later shows whether the lymphoma has responded or come back
Bone marrow reportShows whether the lymphoma has reached the marrow, which changes the stage
List of past treatmentsMany approvals depend on how many lines were given before and whether a BTK inhibitor, rituximab or a transplant was used
Recent blood testsBlood counts and liver and kidney function help the doctor judge whether a medicine can be started safely

Import permit, hospital supply and cost support

Each import is made for one patient by name. Our pharmacist fills in Form 12A on behalf of the patient, who submits it to CDSCO; the regulator's answer is a Form 12B permit valid for this one shipment. See the Form 12A / 12B permit page for the papers involved.

The antibodies here, such as Columvi, Epkinly, Zynlonta, Monjuvi and Poteligeo, are given under hospital supervision, so we usually route them to the treating hospital's pharmacy in a temperature-controlled pack. Our hospital delivery page explains that process. Tablets and capsules such as Jaypirca, Targretin and Zolinza are usually taken at home.

Lymphoma care can stretch over many cycles. If cost is a worry, look at the manufacturer schemes and charity routes listed under patient support and access programs.

How to get these lymphoma medicines in India

1

Prescription
Your doctor prescribes the medicine.

2

Share documents
Send the prescription and latest reports through Online Order.

3

Import paperwork
Our team checks the source and the import permissions.

4

Delivery
Delivered with the right storage, including cold chain.

Read How to Order and Indian import regulations. We also serve patients in Delhi NCR, Bangalore, Chennai, Mumbai, Kolkata, Hyderabad and Pune.

Has your doctor prescribed one of these medicines?

Share the prescription and we will guide you on availability and next steps.

Online Order

Read more about lymphoma

References

  1. IARC Global Cancer Observatory. GLOBOCAN 2024 – India fact sheet (September 2026). https://gco.iarc.who.int/media/globocan/factsheets/populations/356-india-fact-sheet.pdf
  2. IARC Global Cancer Observatory. GLOBOCAN 2024 – Non-Hodgkin lymphoma fact sheet (July 2026). https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf
  3. IARC Global Cancer Observatory. GLOBOCAN 2024 – Hodgkin lymphoma fact sheet (July 2026). https://gco.iarc.who.int/media/globocan/factsheets/cancers/33-hodgkin-lymphoma-fact-sheet.pdf
  4. Arora N, Manipadam MT, Nair S. Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases. Leuk Lymphoma. 2013;54(5):1004-11. https://pubmed.ncbi.nlm.nih.gov/22971239/
  5. Lisa M et al. Distribution of lymphoma subtypes in Bihar – analysis of 518 cases using the WHO classification of lymphoid tumors (2017). J Lab Physicians. 2020;12(2):103-110. https://pubmed.ncbi.nlm.nih.gov/32905403/
  6. Burad DK et al. Peripheral T-cell lymphoma: frequency and distribution in a tertiary referral center in South India. Indian J Pathol Microbiol. 2012;55(4):429-32. https://pubmed.ncbi.nlm.nih.gov/23455774/
  7. Dolai TK et al. Diffuse large B-cell lymphoma – experience from a tertiary care hospital in Eastern India. Indian J Hematol Blood Transfus. 2025;41(4):822-827. https://pubmed.ncbi.nlm.nih.gov/41084583/
  8. Jobanputra K et al. Diffuse large B-cell lymphoma in the elderly: real-world outcomes from a developing country. Clin Lymphoma Myeloma Leuk. 2022;22(10):e898-e906. https://pubmed.ncbi.nlm.nih.gov/35810145/
  9. Nair R et al. Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era. Front Oncol. 2023;13:1248723. https://pubmed.ncbi.nlm.nih.gov/37854680/
  10. Vinodhini M et al. Outcome of non-Hodgkin's lymphoma in adults – real world experience from a cancer centre in North-East India. Indian J Hematol Blood Transfus. 2026;42(3):797-808. https://pubmed.ncbi.nlm.nih.gov/42040712/
  11. Jacob LA et al. Clinical profile and outcome of adult classical Hodgkin's lymphoma: real world single centre experience. Indian J Hematol Blood Transfus. 2024;40(3):392-399. https://pubmed.ncbi.nlm.nih.gov/39011262/
  12. Mahajan A et al. Treating early-stage Hodgkin lymphoma in resource-limited settings: InPOG-HL-15-01 experience. Pediatr Blood Cancer. 2021;68(10):e29219. https://pubmed.ncbi.nlm.nih.gov/34291860/
  13. Rahiman EA et al. Outcome and prognostic factors in childhood B non-Hodgkin lymphoma from India (InPOG-NHL-16-01 study). Pediatr Hematol Oncol. 2022;39(5):391-405. https://pubmed.ncbi.nlm.nih.gov/34978257/
  14. Karulkar A et al. Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies: multicenter real-world evidence. Blood Cancer J. 2026;16(1):177. https://pubmed.ncbi.nlm.nih.gov/42463637/
  15. US FDA prescribing information for each US-approved medicine (DailyMed). https://dailymed.nlm.nih.gov/dailymed/

This page gives general information only and does not replace medical advice. All medicines listed are prescription-only and must be used under a qualified doctor.

Lymphoma Medicines:
Questions Patients Ask

Short answers to what patients and families ask us most.

More FAQs

Meet the NPP Assistant: ask us anything about NPP